AI Biology: What Biohub’s $1.8bn Push Means for Pharma

AI biology now has what Biohub calls the largest international coordinated data programme ever.

On 7 October 2026, Biohub, the U.S. Department of Energy (DOE), and the National Institutes of Health (NIH) set out a $1.8 billion plan to build open and AI-ready biological data. Could this be the future of predictive discovery?

Image

What Does the $1.8 Billion Cross-Sector Collaborative AI Biology Commitment Include?

Biohub announced the expansion with the DOE, the NIH, and new funding partners. The international effort covers funding, data, computing, and new measurement technology.

Reuters reported that the U.S. government and Google joined the Zuckerberg-backed effort.

The timing is deliberate. Biohub launched the Virtual Biology Initiative in April 2026 with its own money. Press coverage at the time framed Biohub’s long-term aim as curing all human disease through AI and biology.

This October announcement adds government and technology partners to that effort.

Who is contributing what?

• Biohub: A $500 million founding commitment to the Virtual Biology Initiative, announced in April 2026. Of this, $400 million funds new measurement technologies and $100 million funds outside research.
• DOE: More than $500 million over five years for fundamental cell research, covering laboratory measurement, modelling, and computation.
• NIH: Coordination of datasets and repositories built with more than $500 million of earlier federal investment.
• Google DeepMind, Isomorphic Labs, and Meta: $300 million combined for technologies and multi-modal datasets.

The sums reach about $1.8 billion, but the mix matters. The NIH share reflects existing investment, not fresh funding.

The NIH also links the effort to the national Bio Genesis Mission Predicting Living Systems science challenge.

That makes the plan as much about organising and standardising data as about generating it.

Who else is involved?

Scientific partners include the Allen Institute, Broad Institute, Gladstone Institutes, Human Cell Atlas, Human Protein Atlas, and Wellcome Sanger Institute.

Additionally, NVIDIA supports the computing needed and Renaissance Philanthropy helps expand funding for data generation.

View interview How AI Is Opening New Opportunities in Fertility Care for Pharma

How AI Is Opening New Opportunities in Fertility Care for Pharma

"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.

Image

The Virtual Cell Depends on Better Data

A virtual cell is a predictive AI model of how a cell behaves. Scientists would ask the model how a cell responds to a drug or a genetic change. They would then test only the most promising answers in the lab.

NIH leaders say such models could deliver faster medical breakthroughs than laboratory experiments alone.

The catch is data. Biohub’s Alex Rives has said accurate models need orders of magnitude more data than exists today.

The initiative therefore targets cell responses to interventions across far more cell types and conditions than researchers have studied so far. It also aims to build instruments that observe cells faster, at larger scale, and with greater accuracy.

Image

Why is intervention data the missing piece?

Many biological datasets describe cells as they are but predictive models need to learn what cells do when something changes.

That means measuring responses to drugs, genetic edits, and other interventions across many cell types and conditions.

The same intervention can produce different outcomes in different cells. A model trained on narrow data will miss that variation. This is why the partners stress breadth, standardisation, and scale together.

Measurement technologies in focus

Biohub’s $400 million technology budget backs three areas:

• Cryo-electron tomography, which resolves near-atomic detail inside cells.
• Large-scale microscopy, which can image millions to billions of cells in living tissue.
• Engineering tools that build and perturb biology from molecules to whole organisms.

How Will the DOE, NIH, and Biohub Divide the Biological Work?

The three lead partners play distinct roles in the AI biology effort. The DOE supplies compute, laboratories, and automation; the NIH supplies existing biomedical data, and Biohub supplies the standards that connect it all. Each part fits together. 

DOE: compute, facilities, and autonomous labs

DOE leads through the Genesis Mission, a cross-agency programme launched by Executive Order.

The DOE release says this partnership delivers on that order, bringing exascale supercomputing, X-ray and neutron scattering, cryo-electron microscopy, and autonomous laboratories across the national laboratory system.

The DOE announcement names user facilities such as the Joint Genome Institute and the Environmental Molecular Sciences Laboratory. It also lists data platforms called BRIDGE and LAMBDA, plus an autonomous laboratory project called OPAL.

NIH: existing data and standards

The NIH contributes through its Bio Genesis Mission. It will draw on repositories catalogued by the National Library of Medicine and the National Center for Biotechnology Information. Common Fund programmes already build biological atlases and shared data standards.

Biohub will work with the NIH to standardise datasets for AI training.

Biohub: standards and community

Biohub is building the innovative layer that lets partner datasets work together. That means shared standards, common identifiers, and one point of access.

It also brings a track record. Past projects include Tabula Sapiens, OpenCell, and Zebrahub, and it maintains CELLxGENE and the CryoET Data Portal.

Why the public and private mix matters

The partners cover three types of capacity. Government agencies bring national laboratories, supercomputers, and extensive curated datasets.

On the private industry side, philanthropy brings flexible funding and community convening and technology companies bring AI expertise and computing know-how.

No single group holds all three, which explains the coalition.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Image

What Does Open AI-Ready Data Mean for Pharma Strategies?

While no single or specific pharma use cases have been set out in detail. The analysis below is Pharmatica’s reading of the stated aims.

Where value may shift

Open data lowers the entry cost for predictive biology.

Every company, including competitors, can use the same base datasets. Advantage may move towards proprietary data, validated models, and speed of translation, not access to public data alone.

The NIH says these models could help scientists identify drug targets and interventions, then prioritise ideas for laboratory and clinical testing. For R&D leaders, that will help with earlier computational triage and fewer low-probability experiments.

Industry is already inside the tent. Isomorphic Labs, an Alphabet company that uses AI for drug discovery, joined as a founding member. Its president says the project needs data at a scale no single organisation can produce today. Read more in our HealthTech & AI insights.

Image

What could the initiative mean across the R&D pipeline?

The clearest near-term fit is target and intervention discovery.

If a model can predict cell responses, teams can screen ideas digitally before they commit bench time. That could widen the number of hypotheses a team tests while keeping laboratory costs steady.

Biohub offers an early illustration. In August 2026, it described how AI is helping scientists find drug combinations that hit several malignant cell states in a tumour at once. Predictive cell models could extend that logic to many more diseases.

The programme builds the data foundation first. Models trained on it, and the drug programmes that follow, will take time.

Building an ecosystem advantage

Partnership strategy matters as much as science.

Companies that contribute data, share expertise, or join consortia early will understand the standards sooner. They will also spot the first reliable models before competitors do. Teams without a plan risk watching the field mature from the sidelines.

Questions for the leadership team

Boards and R&D heads can start with three questions.

• Which programmes rely on hypotheses that predictive models could test early?
• Which internal datasets could follow shared standards without exposing intellectual property?
• Who owns partnership strategy for AI biology across research, data, and business development?

Risks and open questions

Several questions remain.

Virtual cell models are still in development and the announcements set out no performance benchmarks. Any predictions yet to be generated will still need laboratory and clinical validation.

Open data also raises governance questions. The releases do not detail access terms for commercial users, intellectual property, or patient data safeguards.

Timing is another unknown, since the DOE and Biohub commitments run over five years.

Finally, the headline figure includes earlier spending, so new cash is smaller than $1.8 billion.

What Should Pharma Leaders Do to Keep Up With AI Biology?

The Biohub, DOE, and NIH programme aims to build the data layer that AI biology needs. The initiative aims to bring technology and standards into the mix. DOE adds compute, facilities, and autonomous labs, while the NIH contributes existing biomedical data.

Google DeepMind, Isomorphic Labs, and Meta add $300 million.

For any R&D teams hoping to develop AI biology platforms, they should review how ready their perturbation, imaging, and omics data are for shared identifiers and standards. Define where predictive models could cut experiments in your pipeline.

Track the first dataset releases, and explore partnerships with the academic groups involved.

The prize is a shorter path from idea to evidence. The risk is a slow response while open resources level the data field. Prepare now to be ready when the first datasets and models arrive.

At Pharmatica, we track the technologies and policies reshaping pharmaceutical R&D. Our Insights connect data, regulation, and market dynamics so decision-makers can act with confidence.

Pharmatica: Insight. Connection. Impact.

Image